|

NAs Clinical Trials

4 actively recruiting trials

Also known as: ETV/TDF/TAF

Pipeline

Phase 2: 2

Top Sponsors

  • The Second Affiliated Hospital of Chongqing Medical University2
  • Beijing 302 Hospital2

Indications

  • Liver Disease4
  • Chronic Hepatitis b4
  • Anti-PD-1 Antibody2
  • Peg-IFNα1

Other4 trials

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
Phase 2
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Phase 2
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
N/A
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.